Adult mongrel dogs were used. After the measurement of hemodynamic parameters [cardiac output (CO), left ventricular pressure (LVP), and the maximum rates of increase and decrease in LVP (±LVdp/dt)], coronary vascular beds were washed out with a hypothermic (4°C) University of Wisconsin (UW) solution following cardiac arrest in response to cold (4°C) glucose–insulin–potassium solution. The heart was then excised and preserved in hypothermic (4°C) UW solution for 12 h. FK3311 (3 mg/kg) was administered intravenously to five dogs prior to reperfusion, while vehicle was administered intravenously to a control group (n = 5). After 3 h of orthotopic transplantation using cardiopulmonary bypass, the hemodynamic parameters were compared with preoperative values of the donor animals under the condition of 10 mm Hg right atrial pressure and 5 μg/kg/min dopamine support.
The recovery rates of CO and ±LVdP/dt were significantly (P < 0.05) higher in the FK-treated dogs than in the controls (CO: 93 ± 6 versus 66 % ± 4 % ; +LVdp/dt: 125 ± 8 versus 77 ± 10 % ; and −LVdp/dt: 81 ± 7 versus 52 ± 6 % ; for FK-treated versus control dogs, respectively). The recovery rate of LVP was higher in the FK-treated dogs than in the controls (90 ± 5 versus 72 ± 5 % ), but this difference was not statistically significant. Immunohistochemical staining revealed that COX-2 expression was reduced significantly in the myocardium of FK-treated dogs compared with controls.
Hemodynamic parameters following transplantation were improved significantly in dogs treated with FK3311. Therefore, the inhibition of COX-2 improves transplanted cardiac function following long-term preservation.